arrow
D

David Žihala

massachusetts institute of technology (mit)
H指数:12
被引数:581

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune biomarkers of increased infection risk in multiple myeloma

多发性骨髓瘤中感染风险增加的免疫生物标志物

Blood
IF23.1
2026-04-011
PRE
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

选择性耗竭B细胞亚群是接受anti-BCMA与anti-GPRC5D bsAbs治疗的MM患者感染风险增加的基础

Blood
IF23.1
2025-12-190
OAAI
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma

升高的循环肿瘤细胞反映了多发性骨髓瘤中高增殖和基因组复杂性

2025-09-230
PREAI
An expanded phylogenomic analysis of Heterolobosea reveals the deep relationships, non-canonical genetic codes, and cryptic flagellate stages in the group

扩展的系统发育分析揭示了该组中的深层关系,非规范遗传密码和隐性鞭毛阶段

2025-03-010
PRE
Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients

造血细胞自体移植物中克隆浆细胞的水平反映了多发性骨髓瘤患者移植前的骨髓微小残留病

2025-01-151
OA
Deubiquitinase BAP1 is crucial for surface expression of T cell receptor (TCR) complex, T cell-B cell conjugate formation, and T cell activation

去泛素酶BAP1对于T细胞受体 (TCR) 复合物的表面表达,T细胞-b细胞结合物的形成和T细胞活化至关重要。

2024-08-270
OA
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

循环肿瘤和免疫细胞用于阴燃性多发性骨髓瘤的微创危险分层

2022-09-0828
OA
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
2022-01-135
OAAI
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
LEUKEMIA
IF13.4
2021-07-1028
PREAI